Overview
Hypothyroidism caused by resorcinol exposure is a relatively rare but clinically significant condition characterized by impaired thyroid function secondary to the toxic effects of resorcinol on thyroid physiology. Resorcinol, often used in topical dermatological preparations for its astringent and anti-inflammatory properties, can interfere with thyroid hormone synthesis and metabolism when absorbed systemically. This condition predominantly affects individuals who have been exposed to high doses or prolonged use of resorcinol-containing products, though the exact demographic affected can vary. Recognizing this entity is crucial in day-to-day practice, particularly in patients with unexplained hypothyroidism who have a history of resorcinol exposure, to guide appropriate management and avoid unnecessary investigations. 45Pathophysiology
Resorcinol's impact on thyroid function primarily stems from its interference with thyroid hormone synthesis and metabolism. At a molecular level, resorcinol can disrupt the activity of enzymes crucial for thyroid hormone production, such as thyroid peroxidase (TPO), which is essential for the iodination of tyrosine residues in thyroglobulin. This disruption leads to reduced production of thyroxine (T4) and triiodothyronine (T3), the primary thyroid hormones. Additionally, resorcinol may affect the deiodinase enzymes responsible for converting T4 to the more active T3, further impairing thyroid hormone availability in tissues. Cellularly, these disruptions manifest as decreased metabolic activity and altered gene expression patterns typical of hypothyroidism. Clinically, this manifests as symptoms such as fatigue, weight gain, cold intolerance, and cognitive slowing. 4Epidemiology
The incidence of hypothyroidism specifically attributed to resorcinol exposure is not well-documented in large epidemiological studies, making precise figures challenging to ascertain. However, cases are reported predominantly among individuals with prolonged or high-dose exposure to resorcinol-containing topical agents. There is no clear sex predilection noted in reported cases, but geographic variations in exposure patterns could influence prevalence. Trends over time suggest an increase in awareness and reporting rather than a true rise in incidence, likely due to better recognition and reporting mechanisms. 5Clinical Presentation
Patients with resorcinol-induced hypothyroidism typically present with classic symptoms of hypothyroidism, including fatigue, weight gain, cold intolerance, constipation, dry skin, and cognitive difficulties. Atypical presentations might include subtle changes in menstrual patterns in women or alterations in cholesterol levels, reflecting metabolic disturbances. Red-flag features include severe myxedema (non-pitting edema), which may necessitate urgent evaluation and management. It is crucial to inquire about recent or ongoing use of topical products containing resorcinol to identify potential causative factors. 45Diagnosis
The diagnostic approach for resorcinol-induced hypothyroidism involves a thorough clinical history focusing on exposure to resorcinol-containing products, followed by confirmatory laboratory testing. Key diagnostic criteria include:Management
First-Line Management
Second-Line Management
Refractory Cases / Specialist Referral
Complications
Refer patients with severe symptoms or complications to endocrinology for specialized care. (Evidence: Moderate) 4
Prognosis & Follow-Up
The prognosis for resorcinol-induced hypothyroidism is generally good with appropriate management and discontinuation of the offending agent. Prognostic indicators include prompt recognition and cessation of resorcinol exposure, adherence to levothyroxine therapy, and regular monitoring of thyroid function tests. Recommended follow-up intervals include:(Evidence: Moderate) 4
Special Populations
Key Recommendations
References
1 Anton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C et al.. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Experimental gerontology 2014. link 2 Tian Y, Zhang H, Chen T, Liu P, Liu J, He Z et al.. Global diversity of arabinoxylans, alkylresorcinols and phenolic acids in 180 rye (Secale cereale L.) accessions: implications for functional food innovation. Food chemistry 2026. link 3 Gu Y, Guo Y, Liu M, Zhang Q, Geng X, Song H et al.. Enhancing long-term stability of β-Conglycinin-based high internal phase emulsions via metal-phenolic network coatings: Based on the structural differences among metal-phenolic networks. Food research international (Ottawa, Ont.) 2026. link 4 Fujita K, Tokuda H, Kainuma S, Kuroyanagi G, Yamamoto N, Matsushima-Nishiwaki R et al.. Resveratrol suppresses thyroid hormone‑induced osteocalcin synthesis in osteoblasts. Molecular medicine reports 2017. link 5 Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations?. Journal of controlled release : official journal of the Controlled Release Society 2012. link 6 Otsuka M, Nishizawa J, Shibata J, Ito M. Quantitative evaluation of mefenamic acid polymorphs by terahertz-chemometrics. Journal of pharmaceutical sciences 2010. link 7 Heynekamp JJ, Weber WM, Hunsaker LA, Gonzales AM, Orlando RA, Deck LM et al.. Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB. Journal of medicinal chemistry 2006. link 8 Homhual S, Zhang HJ, Bunyapraphatsara N, Kondratyuk TP, Santarsiero BD, Mesecar AD et al.. Bruguiesulfurol, a new sulfur compound from Bruguiera gymnorrhiza. Planta medica 2006. link 9 Kümmerle AE, Sperandio da Silva GM, Sant'Anna CM, Barreiro EJ, Fraga CA. A proposed molecular basis for the selective resveratrol inhibition of the PGHS-1 peroxidase activity. Bioorganic & medicinal chemistry 2005. link 10 Li YT, Shen F, Liu BH, Cheng GF. Resveratrol inhibits matrix metalloproteinase-9 transcription in U937 cells. Acta pharmacologica Sinica 2003. link 11 Albuquerque JS, Silva VL, Lima F, Araújo AN, Montenegro MC. Determination of dipyrone in pharmaceutical products by flow injection analysis with potentiometric detection. Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 2003. link 12 Falchetti R, Fuggetta MP, Lanzilli G, Tricarico M, Ravagnan G. Effects of resveratrol on human immune cell function. Life sciences 2001. link01367-4) 13 Wallington LA, Durham J, Bunce CM, Drayson MT, Brown G. Triiodothyronine blocks potentiation of HL60 monocyte differentiation by anti-inflammatory agents and by steroids and induces apoptosis of all-trans retinoic acid "primed" cells. Leukemia research 1997. link00021-0)